Buprenorphine Lipid Formulation for Neonatal Abstinence Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neonatal abstinence syndrome (NAS) require frequent administration of opioids, leading to prolonged hospital stays and disruption of mother-baby bonding, with a need for treatments that minimize hospital stay and medical practitioner time, and reduce the frequency of dosages to prevent missed follow-up treatments.
Innovation Solution
A controlled-release, injectable formulation comprising 30-50 wt% diacyl glycerol, 30-50 wt% phosphatidylcholine, 5-15 wt% ethanol, and 0.05-0.5 wt% buprenorphine, providing a therapeutically effective opioid release for at least 4 days, allowing for a single or reduced number of injections and minimizing opioid reliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent administration of short-acting opioids is used to treat NAS, then withdrawal symptoms are controlled, but hospital stay is prolonged and mother-baby bonding is disrupted
Solution Approach 1:
The patent changes the key parameter of opioid duration of action from short-acting (hours) to long-acting (days) by using extended-release formulations. This allows the drug to maintain therapeutic levels over an extended period, reducing the frequency of administration from multiple times daily to once daily or less, thereby reducing hospital stay duration while maintaining symptom control
Solution Approach 2:
The extended-release opioid formulations provide continuous therapeutic action over an extended period through controlled release mechanisms. This continuous action maintains stable plasma concentrations of the opioid, ensuring reliable control of withdrawal symptoms without requiring frequent re-administration, thus reducing hospital stay duration
2Reliability
If frequent dosing is required for NAS treatment, then withdrawal symptoms are managed, but treatment adherence is compromised due to missed follow-up appointments
Solution Approach 1:
The patent changes the dosing frequency parameter from frequent (multiple times daily) to infrequent (once daily or less) by using long-acting opioid formulations. This reduction in dosing frequency makes it much easier for patients to adhere to the treatment regimen, as missed doses are less likely to occur and the treatment is more compatible with daily routines
Solution Approach 2:
The extended-release formulations are designed to release the opioid over an extended period in advance, creating a reservoir of drug that maintains therapeutic levels throughout the day. This preliminary action of loading the extended-release formulation ensures that the patient receives continuous medication coverage without needing to take multiple doses throughout the day
3Ease of operation
If long-acting opioids are used to reduce dosing frequency, then treatment adherence improves, but the formulation complexity increases
Solution Approach 1:
The patent employs composite material systems combining opioids with polymers or lipids that provide extended-release properties. These composite formulations integrate the drug with release-controlling materials to achieve long-acting effects. The complexity is managed through standardized formulation platforms that can be applied across different opioid medications
Solution Approach 2:
The patent changes the physical and chemical parameters of the opioid formulation, such as using lipid-soluble esters or polymer conjugates that alter the release profile. These parameter changes transform the pharmacokinetic properties of the opioid from short-acting to long-acting, enabling reduced dosing frequency while using established pharmaceutical formulation techniques
Data Source
AI summary
A lipid controlled-release formulation comprising: a) about 30 to about 50 wt % of at least one diacyl glycerol; b) about 30 to about 50 wt % of at least one phosphatidylcholine; c) about 5 to about 15 wt % ethanol; d) about 0.05 to about 0.5 wt % buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.